Understanding sorafenib-induced ferroptosis and resistance mechanisms: implications for cancer therapy
Q Li, K Chen, T Zhang, D Jiang, L Chen, J Jiang… - European Journal of …, 2023 - Elsevier
Sorafenib is an important first-line treatment option for liver cancer due to its well-
characterized safety profile. While novel first-line drugs may have better efficacy than …
characterized safety profile. While novel first-line drugs may have better efficacy than …
[HTML][HTML] Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line
treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal …
treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal …
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis
K Liu, Y Zhu, H Zhu - Frontiers in Immunology, 2023 - frontiersin.org
Introduction The existence of many phase III randomized controlled trials (RCTs) of first-line
treatment for unresectable hepatocellular carcinoma (HCC) puzzle doctors and patients in …
treatment for unresectable hepatocellular carcinoma (HCC) puzzle doctors and patients in …
Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis
Y Li, X Liang, H Li, X Chen - Cancer, 2022 - Wiley Online Library
Background The cost effectiveness of atezolizumab plus bevacizumab (atezo‐beva) versus
nivolumab treatment for advanced or unresectable hepatocellular carcinoma is still …
nivolumab treatment for advanced or unresectable hepatocellular carcinoma is still …
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian …
G Cabibbo, B Daniele, M Borzio… - Digestive and Liver …, 2024 - Elsevier
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-
related death. The remarkable improvements in treating HCC achieved in the last years …
related death. The remarkable improvements in treating HCC achieved in the last years …
Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review
H Gong, SC Ong, F Li, Y Shen, Z Weng, K Zhao… - Health Economics …, 2024 - Springer
Since 2017, immune checkpoint inhibitors (ICIs) have been available for the treatment of
advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into …
advanced hepatocellular carcinoma (HCC) or unresectable HCC, but their adoption into …
The EORTC QLU-C10D: the Hong Kong valuation study
Abstract Objective The EORTC QLU-C10D is a new preference-based measure derived
from the EORTC QLQ-C30. Country-specific value sets are required to support the cost-utility …
from the EORTC QLQ-C30. Country-specific value sets are required to support the cost-utility …
An overview: management of patients with advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has constituted a significant health burden worldwide, and
patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver …
patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver …
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma
A Roy - Journal of Clinical and Experimental Hepatology, 2022 - pmc.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and remains a
significant cause of cancerrelated death globally. The incidence of HCC has been on the …
significant cause of cancerrelated death globally. The incidence of HCC has been on the …
Sintilimab plus bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Y Peng, X Zeng, L Peng, Q Liu, L Yi, X Luo… - Frontiers in …, 2022 - frontiersin.org
Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar
significantly improved the median progression-free survival and median overall survival …
significantly improved the median progression-free survival and median overall survival …